tiprankstipranks
Trending News
More News >

Isofol Medical Advances Arfolitixorin Clinical Study

Story Highlights
Isofol Medical Advances Arfolitixorin Clinical Study

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Isofol Medical AB ( (SE:ISOFOL) ).

Isofol Medical AB has successfully completed the first cohort in its phase Ib/II clinical study of arfolitixorin, a potential treatment for metastatic colorectal cancer, at Charité – Universitätsmedizin Berlin. The positive recommendation from the Safety Review Committee allows Isofol to proceed to the next dose cohort, marking a significant milestone in the study’s progression and potentially impacting the treatment landscape for colorectal cancer.

More about Isofol Medical AB

Isofol Medical AB is a biotechnology company focused on improving the quality of life and prognosis for patients with severe forms of cancer. The company is developing arfolitixorin, a drug candidate aimed at enhancing the efficacy of first-line standard treatments for various solid tumors, particularly in colorectal cancer, which is the third most common cancer worldwide.

Average Trading Volume: 615,826

Current Market Cap: SEK176.9M

For a thorough assessment of ISOFOL stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1